MarketCap
Facebook
X
Telegram
Royalty Pharma plc EV/EBITDA Ratio | RPRX
Annual EV/EBITDA Ratio Royalty Pharma plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18.1 | 16.6 | 12.9 | 70.7 | 15.1 | 13.9 | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 70.7 | 12.9 | 24.6 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Grifols, S.A.
GRFS
|
13.7 | $ 8.74 | 0.63 % | $ 5.94 B |  Spain |
 |
Incyte Corporation
INCY
|
11.3 | $ 120.28 | -1.32 % | $ 23.5 B |  USA |
 |
AC Immune SA
ACIU
|
-5.33 | $ 2.32 | -4.92 % | $ 234 M |  Schweiz |
 |
Aldeyra Therapeutics
ALDX
|
-8.12 | $ 0.64 | 0.53 % | $ 38.4 M | USA |
 |
Aptose Biosciences
APTO
|
1.65 K | - | -45.71 % | $ 1.2 M |  Canada |
 |
Precision BioSciences
DTIL
|
-0.315 | $ 9.47 | -2.17 % | $ 121 M | USA |
 |
AIM ImmunoTech
AIM
|
-1.18 | $ 0.14 | -11.15 % | $ 227 K | USA |
 |
Ascendis Pharma A/S
ASND
|
-102 | $ 256.21 | -1.4 % | $ 15.5 B |  Danmark |
 |
ANI Pharmaceuticals
ANIP
|
9.16 | $ 71.31 | 5.19 % | $ 1.43 B | USA |
 |
Actinium Pharmaceuticals
ATNM
|
-0.744 | $ 1.56 | 1.3 % | $ 48.7 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-2.4 | $ 1.31 | -0.76 % | $ 349 M |  Britain |
 |
Monopar Therapeutics
MNPR
|
-20.5 | $ 71.42 | -3.16 % | $ 529 M | USA |
 |
BridgeBio Pharma
BBIO
|
-30 | $ 78.67 | 0.95 % | $ 15.1 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
8.17 | $ 7.53 | -1.38 % | $ 1.58 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
0.703 | $ 3.68 | -2.39 % | $ 255 M | Britain |
 |
Coherus BioSciences
CHRS
|
-1.86 | $ 0.64 | -21.66 % | $ 75 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-316 | $ 27.45 | 4.77 % | $ 3.49 B | USA |
 |
Cellectis S.A.
CLLS
|
-15.8 | $ 1.12 | -0.45 % | $ 112 M |  France |
 |
BeyondSpring
BYSI
|
-12.6 | $ 0.6 | -2.21 % | $ 24.7 M | USA |
 |
Alkermes plc
ALKS
|
19.2 | $ 46.48 | 0.67 % | $ 7.66 B |  Irlanda |
 |
Altimmune
ALT
|
-3.49 | $ 1.94 | -8.51 % | $ 171 M | USA |
 |
Cardiff Oncology
CRDF
|
-2.37 | $ 0.79 | -0.77 % | $ 52.8 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
-1.5 | $ 0.5 | -5.43 % | $ 5.53 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-0.593 | $ 9.41 | -0.84 % | $ 258 M |  Israel |
 |
Arrowhead Pharmaceuticals
ARWR
|
50 | $ 49.04 | -0.41 % | $ 6.56 B | USA |
 |
Atara Biotherapeutics
ATRA
|
3.26 | $ 8.18 | -0.73 % | $ 103 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
37 | $ 16.3 | -1.93 % | $ 2.19 B | Canada |
 |
Cullinan Management
CGEM
|
-3.52 | $ 11.34 | -3.32 % | $ 683 M | USA |
 |
BioNTech SE
BNTX
|
-12.2 | $ 87.2 | -0.36 % | $ 21.1 B |  Germany |
 |
Collegium Pharmaceutical
COLL
|
38.8 | $ 24.47 | -0.97 % | $ 775 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-1.4 | $ 3.95 | 12.07 % | $ 52.6 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
-29.5 | $ 1.21 | -11.68 % | $ 55.3 M | Israel |
 |
AnaptysBio
ANAB
|
45.1 | $ 48.4 | 0.9 % | $ 1.4 B | USA |
 |
Assembly Biosciences
ASMB
|
-25.1 | $ 21.33 | -2.11 % | $ 239 M | USA |
 |
Adagene
ADAG
|
-8.38 | $ 2.02 | -4.95 % | $ 119 M |  China |
 |
Benitec Biopharma
BNTC
|
-7.59 | $ 9.31 | -5.67 % | $ 433 M | USA |
 |
Denali Therapeutics
DNLI
|
-4.29 | $ 19.85 | -2.36 % | $ 3.43 B | USA |
 |
Amarin Corporation plc
AMRN
|
-125 | $ 11.75 | 0.09 % | $ 4.88 B | Irlanda |
 |
ImmuCell Corporation
ICCC
|
15.7 | $ 10.4 | 1.76 % | $ 93.9 M | USA |
 |
Editas Medicine
EDIT
|
-1.41 | $ 2.5 | -9.09 % | $ 222 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
-3.53 | $ 31.77 | 1.23 % | $ 1.84 B | USA |
 |
Cue Biopharma
CUE
|
-0.704 | $ 18.89 | -6.21 % | $ 1.79 B | USA |
 |
Equillium
EQ
|
-3.87 | $ 1.45 | -3.33 % | $ 83.1 M | USA |
 |
Black Diamond Therapeutics
BDTX
|
10.5 | $ 1.6 | -14.05 % | $ 91 M | USA |
 |
Abeona Therapeutics
ABEO
|
-2.69 | $ 2.46 | -3.35 % | $ 130 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
36 | $ 18.13 | 9.85 % | $ 3.05 B | USA |
 |
Atossa Therapeutics
ATOS
|
-0.367 | $ 2.21 | 3.76 % | $ 19 M | USA |
 |
Cleveland BioLabs, Inc.
CBLI
|
-22.4 | - | -7.31 % | $ 49 M | USA |
 |
Five Prime Therapeutics, Inc.
FPRX
|
-6.28 | - | - | $ 1.77 B | USA |
 |
ADC Therapeutics SA
ADCT
|
-3.2 | $ 1.51 | -9.88 % | $ 192 M | Schweiz |